AI assistant
Sending…
MedCap — Major Shareholding Notification 2024
Sep 16, 2024
3075_iss_2024-09-16_ac14ae9c-ffaa-4f33-b098-1869d70de16b.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer

Issuer MedCap AB (publ)
Holder
Lannebo Kapitalförvaltning AB
Instrument
| Instrument | Aktie SE0009160872 | |
|---|---|---|
| Before the transaction | ||
| Shares | 0 | |
| Voting rights | 0 | |
| Transaction | ||
| Reason for major shareholding notification Corporate action | ||
| Date | 16/09/2024 | |
| Limit for number of shares | 5 % | |
| Limit for number of votes | 5 % | |
| After the transaction | ||
| Quantity | ||
| Shares | 1,272,523 | |
| Directly held voting rights | 1,272,523 | |
| Indirectly held voting rights | 0 | |
| Percentage | ||
| Directly held shares | 8.5938 % | |
| Directly held voting rights | 8.5938 % | |
| Indirectly held voting rights | 0 % |
Resulting distribution of total holdings
| Percentage of voting rights: |
Number of underlying shares: |
|
|---|---|---|
| Shares | 8.5938 % | 1,272,523 |
| Instruments - FITA Ch. 4, section 2, first paragraph, line 2 |
||
| Instruments - FITA Ch. 4, section 2, first paragraph, line 3 |
||
| - Physically settled - Cash settled |
||
| Total | 8.5938 % | 1,272,523 |
Notes (other relevant informations according to law)
Fusionen har skett genom att Lannebo Kapitalförvaltning AB absorberat Lannebo Fonder AB och därmed tagit över förvaltningen av de fonder som tidigare förvaltades av Lannebo Fonder AB. Lannebo Fonder AB:s tidigare innehav via dess fonder har därmed övergått till Lannebo Kapitalförvaltning AB. Det har inte skett några förändringar i förvaltningen, och fonderna förvaltas på samma sätt som tidigare.
Published
16/09/2024 09:34
Contact
Name Daniel Jern Phone 0702299174 Email [email protected]

[email protected] Tfn 08-408 980 37 Fax 08-24 39 25
More from MedCap
Share Issue/Capital Change
2026
May 29
Transaction in Own Shares
2026
May 20
Transaction in Own Shares
2026
May 13
Transaction in Own Shares
2026
May 6
AGM Information
2026
May 4
Interim / Quarterly Report
2026
Apr 29
Interim / Quarterly Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Mar 30
Board/Management Information
2026
Mar 25
Annual Report (ESEF)
2026
Mar 23